PEB - Pacific Edge Ltd

[Minerbarejet]

And seeing as we are on Companion Diagnostics , this from FierceDiagnostics
Report: Companion Testing Market Exceeded One Billion Dollars in 2013
The market for test and pharmaceutical pairs, known as companion diagnostics in the testing industry, has grown significantly. The global companion diagnostic market is valued at about $1.2 billion for 2013. This is up from $950 million in 2011, an increase of 12.5%. This statistic was cited in a new report from healthcare market research firm Kalorama Information, Companion Diagnostic Markets.
The report can be found at: http://www.kaloramainformation.com/r...ductid=8328701.
Companion diagnostics increase the probability of clinical success by identifying patients with the presence of biomarkers or disease-specific therapeutic targets that can dramatically improve outcomes. Companion diagnostics can also decrease costs by identifying the patient population that will most likely benefit from the therapy, and ruling out therapies that are not likely to be effective. This is especially critical given the cost of many new cancer therapies. Companion diagnostics also improve patient outcomes by selectively determining which patients will respond to therapy.
"One of the faster-growing testing areas in terms of revenues is drug/test pairs," according to Mary Ann Crandall, analyst for Kalorama Information. "The emergence of new technology has opened doors for companion diagnostic research, discovery, development and commercialization."
This market is a small part of several larger markets including the IVD market, the immunoassay market and the biomarker market, as all of these markets are intertwined. Kalorama made its market projection from extensive literature reviews and discussions with experts in the field, including microbiologists, pathologists, hospital authorities, reimbursement specialists, research scientists, business development managers and marketing managers.
"There had been a slow market uptake of companion diagnostics because companion tests lacked FDA approval, which prevented pharmaceutical companies from promoting the diagnostic," said Crandall. "But the realization that companion diagnostics can decrease costs by identifying the patient population that will most likely benefit from a therapy and ruling out those therapies not likely to be effective has made companion diagnostics important to the delivery of care."
Kalorama expects even more rapid revenue growth in this area of IVD over the next five years. Companion diagnostic development has become a primary area of focus for developers and many companion diagnostics are now successfully marketed with several of them part of a routine diagnostic and treatment plan.
Find Companion Diagnostic Markets in addition to other industry leading research from Kalorama Information at: http://www.kaloramainformation.com/.

[Carpenterjoe]

Cheers Hancocks,

Seems a little messy, much prefer the direct approach. Or the cellmid arrangement.
Could be sometime before they iron out the wrinkles.

I trust they have this all sorted

[Blue Horseshoe]

yep I am totally deluded but after good research I managed to sell out of this stock and I could have bought back, only a few months later, for a 50% discount to my average sell price.
Happy to be deluded.

No one went broke making a profit.

[Minerbarejet]

yep I am totally deluded but after good research I managed to sell out of this stock and I could have bought back, only a few months later, for a 50% discount to my average sell price.
Happy to be deluded.

For the last time -congratulations and extremely well done.
Now use some of your profits to get those crayfish checked out. I think they are a bit dodgy and giving you a bellyache.
Cheers
Miner

[Carpenterjoe]

Interesting read

http://www.rmresearch.com.au/wp-cont.../cellmid-3.pdf

[stoploss]

Interesting read

http://www.rmresearch.com.au/wp-cont.../cellmid-3.pdf

That report is 6 months old . CDY is still range bound .

[Carpenterjoe]

Yes, I was interested in details around royalties I didn't understand that every dollar cxbladder generates 2-4% could go to Cellmid, Also how these guys see sales growth rates and future price of the product.

[NT001]

That report is 6 months old . CDY is still range bound .

Yes but rangebound between about 2.3c and 3.7c, and trending up steadily in recent months without much news to go on. Could be a bit like PEB, just needing a nudge to start moving. And could be a target for takeover with all that IP.

[see weed]

Unrelated, just tried to say good bye to moosie, but got blocked, and the whole page of good bye's have been deleted.???

[Joshwnz]

Unrelated, just tried to say good bye to moosie, but got blocked, and the whole page of good bye's have been deleted.???

So has the sticky page for the chch ST gathering later in the month, it appears. Did moosie start these pages, and as his profile has gone, so has the pages he started?